Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.40 |
| ▸ | ELANE | P08246 | 5/20 | 0.39 |
| ▸ | FKBP4 | Q02790 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | XIAP | P98170 | 1/20 | 0.34 |
| ▸ | MLX | Q9UH92 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | CMA1 | P23946 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7235515 | 0.91 | TACR1 (0.41) | TACR1ELANEFKBP4XIAPMLX | |
| SCHEMBL398010 | 0.91 | KCNH2 (0.39) | TACR1FKBP4KCNH2MEN1KMT2A | |
| SCHEMBL846697 | 0.87 | FKBP4 (0.51) | TACR1FKBP4CMA1 | |
| SCHEMBL2682605 | 0.87 | TACR1 (0.40) | TACR1FKBP4KCNH2TRPV1CMA1 | |
| SCHEMBL1451494 | 0.85 | MEN1 (0.40) | MEN1KMT2ALMNAMMP9 | |
| SCHEMBL3244930 | 0.84 | ELANE (0.43) | TACR1ELANEFKBP4KCNH2XIAP | |
| SCHEMBL3926322 | 0.83 | TACR1 (0.41) | TACR1ELANEFKBP4XIAPMLX | |
| SCHEMBL2289363 | 0.83 | ELANE (0.42) | ELANEXIAPMLXCMA1 | |
| SCHEMBL5134830 | 0.83 | KDM4E (0.40) | ELANECYP3A4CYP2C9CYP2C19 | |
| SCHEMBL8662040 | 0.82 | ELANE (0.40) | ELANEXIAPMLXCMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 343 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2433138-B1 | METHOD FOR DETECTING A WOUND INFECTION | TECH UNIVERSITÄT GRAZ (AT) | 2016-09-14 | — | — | EP | claimed |
| US-8822173-B2 | Wound dressing or swab for detecting infection | EVA WEHRSCHUTZ-SIGL (AT) | 2014-09-02 | — | — | US | claimed |
| US-20130337484-A1 | METHOD FOR DETECTING A WOUND INFECTION | WEHRSCHUTZ-SIGL, EVA (AT) | 2013-12-19 | — | — | US | claimed |
| US-8497085-B2 | Method for detecting a wound infection | TECHNISCHE UNIVERSITAT GRAZ (AT) | 2013-07-30 | — | — | US | claimed |
| CN-102928586-A | Method for detecting human neutrophil elastase based on nucleic acid aptamer | UNIV SHANXI | 2013-02-13 | — | — | CN | claimed |
| US-20120258483-A1 | METHOD FOR DETECTING A WOUND INFECTION | TECHNISCHE UNIVERSITAT GRAZ (AT) | 2012-10-11 | — | — | US | claimed |
| EP-2433138-A1 | METHOD FOR DETECTING A WOUND INFECTION | Technische Universität Graz (AT) | 2012-03-28 | — | — | EP | claimed |
| WO-2010133589-A1 | METHOD FOR DETECTING A WOUND INFECTION | TECHNISCHE UNIVERSITÄT GRAZ (AT) | 2010-11-25 | — | — | WO | claimed |
| US-6740499-B2 | DETECTING ELASTASE IN PATIENT SPUTUM | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2004-05-25 | — | — | US | claimed |
| US-20020001820-A1 | Method for detecting bacterial exacerbations of chronic lung disease | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2002-01-03 | — | — | US | claimed |
| EP-3897669-B1 | METHODS AND COMPOSITIONS RELATED TO THERAPEUTIC PEPTIDES FOR CANCER THERAPY | UNIV CHICAGO (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12611443-B2 | Methods and compositions related to therapeutic peptides for cancer therapy | THE UNIVERSITY OF CHICAGO | 2026-04-28 | — | — | US | disclosed |
| EP-4705336-A1 | NOVEL THERAPEUTIC POLYPEPTIDE | King, Paul Thomas (AU) | 2026-03-11 | — | — | EP | disclosed |
| US-12516307-B2 | Modified porcine pancreatic elastase proteins | ONCHILLES PHARMA, INC. (US) | 2026-01-06 | — | — | US | disclosed |
| EP-3873394-B1 | SYSTEM FOR ANALYSIS OF BODY FLUIDS AND WOUND-ASSOCIATED BIOMOLECULES | PROGENITEC INC (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-0205555-A4 | SERINE PROTEASE INHIBITORS AND METHODS FOR ISOLATION OF SAME. | SYNERGEN BIOLOG INC (US) | 1987-11-09 | — | — | EP | disclosed |
| EP-0205555-A1 | SERINE PROTEASE INHIBITORS AND METHODS FOR ISOLATION OF SAME. | SYNERGEN BIOLOG INC (US) | 1986-12-30 | — | — | EP | disclosed |
| WO-1986003497-A1 | SERINE PROTEASE INHIBITORS AND METHODS FOR ISOLATION OF SAME | SYNERGEN BIOLOGICALS, INC. (US) | 1986-06-19 | — | — | WO | disclosed |
| EP-0169114-A2 | Human alpha-1-antitrypin derivatives and process for their preparation | TRANSGENE S.A. (FR) | 1986-01-22 | — | — | EP | disclosed |
| WO-1986000337-A1 | HUMAN alpha1-ANTITRYPSIN DERIVATIVES AND PREPARATION PROCESS THEREOF | TRANSGENE S.A. (FR) | 1986-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12611443-B2 | Methods and compositions related to therapeutic peptides for cancer therapy | ELANE, PREP, BRCA1 | TACR1 3680/4885ELANE 1/4885FKBP4 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.